financetom
Business
financetom
/
Business
/
Ryanair's O'Leary says new Boeing management 'continue to disappoint'
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Ryanair's O'Leary says new Boeing management 'continue to disappoint'
Aug 29, 2024 2:38 AM

BRUSSELS, Aug 27 (Reuters) - Ryanair Group Chief

Executive Michael O'Leary on Tuesday said that Boeing's ( BA ) new

management "continue to disappoint" and that deliveries were

behind schedule.

The Irish airline, one of Boeing's ( BA ) largest customers, said

there was a risk it would take delivery of just 20-25 of the 737

MAX aircraft ahead of next summer, rather than the 29 scheduled.

"Things are continuing to slip slightly, it's been

disappointing," O'Leary told Reuters in an interview.

"We're working closely with Stephanie Pope and the new team

in Boeing ( BA ), but they continue to disappoint us," he said,

referring to the head of Boeing Commercial Airplanes, who was

appointed in March.

Boeing ( BA ) last month named aerospace industry veteran Kelly

Ortberg as its chief executive.

Boeing ( BA ) has pledged to grow output by the end of the year,

after wrestling with supply chain snags and operating a slower

assembly line since a Jan. 5 in-flight blowout of a door plug on

a 737 MAX 9 jet that heightened regulatory scrutiny.

O'Leary said Ryanair had received five aircraft in July

instead of the seven scheduled and that it looked like it would

get just five of 10 scheduled for August.

"Boeing ( BA ) have had significant production problems. We think

they're getting to the end of that," he said.

Ryanair said in July that Boeing ( BA ) had warned it some 737 MAX

deliveries due by next spring would be delayed until the peak

summer months of 2025 - a repeat of delays this year that forced

a cut in its summer traffic volumes.

Ryanair, Europe's largest by passenger numbers, already has

150 firm orders for the MAX 10, the largest jet in the 737

family, and options for 150 more, with the first deliveries due

in 2027.

O'Leary said the smaller MAX 7 was supposed to be certified

by the end of this year, but that looks like slipping into the

first half of 2025.

He said it was "impossible to know" if certification of the

MAX 10 would be on time in the first half of 2025. "It's a

day-by-day challenge with Boeing ( BA )."

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Patterson Companies Fiscal Q2 Adjusted Earnings Down, Sales Rise; Lowers Fiscal 2025 Adjusted EPS Guidance
Patterson Companies Fiscal Q2 Adjusted Earnings Down, Sales Rise; Lowers Fiscal 2025 Adjusted EPS Guidance
Dec 5, 2024
07:45 AM EST, 12/05/2024 (MT Newswires) -- Patterson Companies ( PDCO ) reported fiscal Q2 adjusted earnings Thursday of $0.47 per diluted share, down from $0.50 a year earlier. A single analyst polled by FactSet expected $0.47. Net sales for the fiscal quarter ended Oct. 26 was $1.67 billion, up from $1.65 billion a year earlier. Analysts surveyed by FactSet...
Southwest Airlines Raises Q4 Revenue Guidance Amid Strong Leisure Travel Demand
Southwest Airlines Raises Q4 Revenue Guidance Amid Strong Leisure Travel Demand
Dec 5, 2024
07:45 AM EST, 12/05/2024 (MT Newswires) -- Southwest Airlines ( LUV ) said in a regulatory filing Thursday that it increased its Q4 unit revenue growth forecast to a range of 5.5% to 7% from the previous range of 3.5% to 5.5%, citing better-than-expected leisure travel demand and revenue optimization efforts. The carrier said it now expects Q4 capacity to...
Merck Begins Late-Stage Trial to Evaluate Lagevrio for Treatment of COVID-19 in High-Risk Adults
Merck Begins Late-Stage Trial to Evaluate Lagevrio for Treatment of COVID-19 in High-Risk Adults
Dec 5, 2024
07:47 AM EST, 12/05/2024 (MT Newswires) -- Merck ( MRK ) said Thursday that it has started a late-stage clinical trial to assess investigational oral antiviral COVID-19 medicines Lagevrio or molnupiravir for the treatment of adults with COVID-19 who are at high risk for disease progression. Lagevrio is being developed by Merck ( MRK ) in collaboration with Ridgeback Biotherapeutics....
CME Group Board Approves $3 Billion Stock Buyback Plan, $2.10 Billion Annual Variable Dividend
CME Group Board Approves $3 Billion Stock Buyback Plan, $2.10 Billion Annual Variable Dividend
Dec 5, 2024
07:50 AM EST, 12/05/2024 (MT Newswires) -- CME Group ( CME ) said Thursday its board approved an annual variable dividend totaling $2.10 billion as well as a share repurchase program of up to $3 billion of Class A common stock. The dividend amounts to $5.80 per share and is payable Jan. 16, 2025, to shareholders of record as of...
Copyright 2023-2026 - www.financetom.com All Rights Reserved